Date: 2014-02-05
Type of information: Financing round
Company: Anergis (Switzerland)
Investors: Sunstone Capital (Denmark), BioMedInvest (Switzerland), Renaissance PME/Vinci Capital (Switzerland)
Amount: CHF 8 million (€6.5 million)
Funding type: financing round
Planned used: Anergis will use the proceeds to further advance the clinical development of its lead product AllerT, a vaccine to treat birch pollen allergy, and to advance two additional vaccine candidates against house dust mite and ragweed allergies. For AllerT, the funds will specifically allow the preparation of Phase III trials and the conduct of a long-term efficacy follow-up trial of patients who participated in the recently completed field-based Phase II study. The results from this second follow-up season are expected to be available in the third quarter of 2014.
Others:
Therapeutic area: Allergic diseases - Immunological diseases